Inner-City Pharmacies: Can They Meet the OBRA ’90 Mandates?

A recent survey of biotechnology-derived medicines and vaccines under development showed that the largest fraction of these were monoclonal antibodies for the detection and/or treatment of cancer. This article describes the role and function of the nuclear pharmacist in the initiation, development, and conduct of a prototype clinical trial in which a radiolabeledmonoclonal antibody (MAb) is used as a diagnostic imaging agent to detect the site of a tumor in a patient who is being managed in a hospital outpatient setting. Examples are used to illustrate selected pharmaceutical care issues in this investigational environment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Inner-City Pharmacies: Can They Meet the OBRA ’90 Mandates?

Cited by 3 publications

References 3 publications

New York City Pharmacists and OBRA '90: One Year Later

New York City Pharmacists and OBRA '90: One Year Later

New York City Pharmacists and Prospective Drug Utilization Review under Obra '90

Investigational Radioimmunopharmaceuticals: Pharmaceutical Care Responsibilities and Opportunities

Contact Info

Product

Resources

About